Harvard | Mr. Australian Navy
GMAT 770, GPA 3.74
Harvard | Mr. Forbes U30 & Big Pharma
GMAT 640, GPA 3.4
Harvard | Mr. Brightside
GMAT 760, GPA 3.93
Wharton | Mr. Asset Manager – Research Associate
GMAT 730, GPA 3.6
Ross | Mr. FP&A
GMAT 730, GPA 3.5
Kenan-Flagler | Mr. 10 Years In Finance
GMAT Not Required / Waived, GPA 2.65
Berkeley Haas | Mr. Hanging By A Thread
GMAT 710, GPA 3.8
NYU Stern | Ms. Civil Servant To Fortune 50
GRE Writing May 31st, GPA Undergrad: 3.0, Graduate: 3.59
Harvard | Ms. Social Enterprise/Healthcare
GRE 324, GPA 3.5
Harvard | Ms. FMCG Enthusiast Seeking Second MBA
GMAT 730, GPA 3.1
Stanford GSB | Mr. Former SEC Athlete
GMAT 620, GPA 3.8
Harvard | Mr. Supply Chain Photographer
GMAT 700, GPA 3.3
McCombs School of Business | Ms. Registered Nurse Entrepreneur
GMAT 630, GPA 3.59
MIT Sloan | Ms. Designer Turned Founder
GMAT 720, GPA 3.5
Kellogg | Ms. Not-For-Profit
GMAT TBD, GPA 4.0
INSEAD | Mr. Big Chill 770
GMAT 770, GPA 3-3.2
Harvard | Mr. Captain Mishra
GMAT 760, GPA 4.0
Ross | Mr. Dragon Age
GRE 327, GPA 2.19/4.0
Wharton | Ms. Type-A CPG PM
GMAT 750, GPA 3.42
Harvard | Ms. 2+2 Trader
GMAT 770, GPA 3.9
Berkeley Haas | Mr. Young Software Engineer
GRE 330, GPA 3.60
NYU Stern | Mr. Indian Analytics Consultant
GMAT 700, GPA 3.0
Chicago Booth | Ms. Start-Up Entrepreneur
GRE 322, GPA 3.4
Columbia | Mr. RAV4 Chemical Engineer
GMAT 750, GPA 3.62
Wharton | Mr. Big 4 M&A
GMAT 760, GPA 3.5
Harvard | Mr. Aerospace Project Manager
GMAT 740, GPA 3.58
Columbia | Mr. Ambitious Veteran
GMAT 700, GPA 3.1

NFL Owner Kraft Gives HBS $20 Million

NFL Owner Robert Kraft

NFL Owner Robert Kraft

As Harvard Business School MBA and corporate titan Robert Kraft’s wife lay dying of cancer, Kraft frequently consulted with former HBS professor Eric Lander, founding director of the biomed-focused Harvard/MIT Broad Institute. Myra Kraft passed away in 2011, but the relationship that grew between her husband and Lander has now led to a major gift to HBS, an endowment intended to deliver a boost to a cutting-edge field of medicine – and bring new opportunities for MBAs.

The school announced today (Nov. 18) a $20 million endowment to HBS from the Robert and Myra Kraft Foundation, to create the Kraft Endowment for Advancing Precision Medicine. Precision medicine, also called “personalized medicine,” combines a patient’s genetic, lifestyle, and environment information to enable targeted, individualized medical treatment.

“For all diseases this is the new approach that virtually all big pharma and certainly startup R&D efforts are going after – targeted therapies, not large broad-based therapies,” says HBS management professor Richard Hamermesh. “Most drugs work for no more than 60% of the people that take them. Diseases and humans all different. It’s not like one size serves all.”

Harvard Business School - Ethan Baron photo

Harvard Business School – Ethan Baron photo

ANOTHER STEP TOWARD $1 BILLION

The donation pledge brings Harvard closer to the goal of a capital campaign announced last year to bring in $1 billion over five years. By the end of this past June, HBS had raised $861 million, with $261 million of that brought in after the official April 2014 announcement.

Billionaire donor Kraft, who received his HBS MBA in 1965 and owns the New England Patriots, wants to see results from his donation as quickly as possible, Hamermesh says. “He doesn’t want more people suffering the same fate that his wife did,” Hamermesh adds.

Precision medicine is used extensively in cancer treatment. “In most cases, tumors are (genetically) sequenced so you understand exactly what the genetic mutations are in a particular cancer, and then you treat the mutations,” Hamermesh says. “In time, cancers will be known not so much as lung cancer or liver cancer or whatever, but they’ll be known by the mutations in the genetic pathways that are being disrupted.”

Genetics-based precision treatment is also used for cystic fibrosis, which is caused by irregularities in a single gene. Precision medicine identified three different mutations, and there are treatments for two of them, meaning that about 65% of U.S. children diagnosed with the disease will be treated as long as they live, but never develop symptoms, Hamermesh says. AIDS, too, is addressed with precision medicine – the virus is sequenced to identify mutations, and drug cocktails prescribed based on which mutations are present.

EXPANSION OF NEW MEDICINE FIELD MOSTLY A BUSINESS PROBLEM

Barriers to expansion of precision medicine are 70% business problems and only 30% science problems, Hamermesh says. “You need lots of data that organizations and institutions need to share to do the numerical analysis linking aberrations and mutations in genes to specific diseases,” he says. “That’s where the B-school comes in.

Page 1 of 2